Article

Quantitative mass spectrometry to interrogate proteomic heterogeneity in metastatic lung adenocarcinoma and validate a novel somatic mutation CDK12-G879V

2018-08-22

Abstract excerpt

Lung cancer is the leading cause of cancer death both in men and women. Tumor heterogeneity is an impediment to targeted treatment of all cancers, including lung cancer. Here, we sought to characterize changes in tumor proteome and phosphoproteome by longitudinal, prospective collection of tumor tissue of an exceptional responder lung adenocarcinoma patient who survived with metastatic lung adenocarcinoma for more...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ea79e9ab-e02f-5a2a-b566-71f38c8d2bc0
DOI: 10.1101/398313

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Quantitative mass spectrometry to interrogate proteomic heterogeneity in metastatic lung adenocarcinoma and validate a novel somatic mutation CDK12-G879VDOI 10.1101/398313Read

Proteogenomic characterization identifies clinical subgroups in EGFR and ALK wild-type never-smoker lung adenocarcinoma.Semantic proximity Read

Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors.Semantic proximity Read

Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures.Semantic proximity Read

Integrated proteogenomic analysis of metastatic thoracic tumors identifies APOBEC mutagenesis and copy number alterations as drivers of proteogenomic tumor evolution and heterogeneitySemantic proximity Read

Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors.Semantic proximity Read

Integrative proteomic characterization of human lung adenocarcinoma with KRAS G12 mutations reveals molecular pathogenesis.Semantic proximity Read

High-resolution lung adenocarcinoma expression subtypes identify tumors with dependencies on <i>MET, CDK4, CDK6</i> , and <i>PD-L1</i>Semantic proximity Read

Developments for Personalized Medicine of Lung Cancer Subtypes: Mass Spectrometry-Based Clinical Proteogenomic Analysis of Oncogenic Mutations.Semantic proximity Read

Evolutionary proteogenomic landscape from pre-invasive to invasive lung adenocarcinomaSemantic proximity Read

Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma.Semantic proximity Read

Pan-cancer proteogenomics expands the landscape of therapeutic targetsSemantic proximity Read

Current status of clinical proteogenomics in lung cancerSemantic proximity Read